These reports suggest that MGAT2 is a key molecule involved in fat sensing in the gut and support the concept that pharmacological inhibition of MGAT2 could be used as a treatment for obesity and its related metabolic diseases. This evidence concerns the gene MGAT2 and obesity due to melanocortin 4 receptor deficiency.